Literature DB >> 9227733

Neuromuscular blockade with acute respiratory failure in a patient receiving cibenzoline.

T Similowski1, C Straus, V Attali, F Girard, F Philippe, G Deray, D Thomas, J P Derenne.   

Abstract

Cibenzoline is a class Ic antiarrhythmic agent that can be used to treat supraventricular arrhythmias. A case is reported of cibenzoline overdose in a patient with impaired renal function, leading not only to the usual cardiac and metabolic symptoms (bradycardia and hypoglycaemia), but also to a myastheniform syndrome with acute respiratory failure. Neuromuscular blockade was demonstrated by repetitive supramaximal stimulation of the median nerve, and diaphragmatic involvement was evidenced by applying the same protocol to the phrenic nerve. Muscle strength recovered as serum cibenzoline levels decreased, allowing the patient to be weaned from the ventilator. This observation suggests that cibenzoline, like other antiarrhythmic agents, can be responsible for neuromuscular blockade, and should therefore be used with caution in patients with neuromuscular and respiratory diseases or with impaired renal function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9227733      PMCID: PMC1758590          DOI: 10.1136/thx.52.6.582

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  22 in total

1.  Timing of chest film follow-up after transthoracic needle aspiration.

Authors:  L M Perlmutt; S D Braun; G E Newman; E J Oke; N R Dunnick
Journal:  AJR Am J Roentgenol       Date:  1986-05       Impact factor: 3.959

2.  Lung lesions: cytologic diagnosis by fine-needle biopsy.

Authors:  J H Stanley; G D Fish; J G Andriole; R P Gobien; W L Betsill; S A Laden; S I Schabel
Journal:  Radiology       Date:  1987-02       Impact factor: 11.105

3.  Delayed pneumothorax after transbronchial lung biopsy.

Authors:  H Levy; J M Kallenbach; C Feldman; P Pincus; M Hurwitz
Journal:  Thorax       Date:  1986-08       Impact factor: 9.139

4.  Acute respiratory failure following intravenous verapamil in Duchenne's muscular dystrophy.

Authors:  F Zalman; J K Perloff; N N Durant; D S Campion
Journal:  Am Heart J       Date:  1983-03       Impact factor: 4.749

5.  Outpatient needle biopsy of the lung: its safety and utility.

Authors:  G M Stevens; R J Jackman
Journal:  Radiology       Date:  1984-05       Impact factor: 11.105

6.  Cibenzoline-induced hypoglycemia.

Authors:  D E Hilleman; S M Mohiuddin; I S Ahmed; J M Dahl
Journal:  Drug Intell Clin Pharm       Date:  1987-01

7.  Transthoracic needle aspiration biopsy of benign and malignant lung lesions.

Authors:  N F Khouri; F P Stitik; Y S Erozan; P K Gupta; W S Kim; W W Scott; U M Hamper; R B Mann; J C Eggleston; R R Baker
Journal:  AJR Am J Roentgenol       Date:  1985-02       Impact factor: 3.959

8.  Effects of hypocalcemia on diaphragmatic strength generation.

Authors:  M Aubier; N Viires; J Piquet; D Murciano; F Blanchet; C Marty; R Gherardi; R Pariente
Journal:  J Appl Physiol (1985)       Date:  1985-06

9.  Presynaptic and postsynaptic actions of procainamide on neuromuscular transmission.

Authors:  D C Lee; Y I Kim; H H Liu; T R Johns
Journal:  Muscle Nerve       Date:  1983 Jul-Aug       Impact factor: 3.217

10.  Transthoracic needle aspiration biopsy: accuracy of cytologic typing of malignant neoplasms.

Authors:  J R Thornbury; D P Burke; B Naylor
Journal:  AJR Am J Roentgenol       Date:  1981-04       Impact factor: 3.959

View more
  2 in total

1.  Identification of prolonged phrenic nerve conduction time in the ICU: magnetic versus electrical stimulation.

Authors:  Alexandre Demoule; Capucine Morelot-Panzini; Hélène Prodanovic; Christophe Cracco; Julien Mayaux; Alexandre Duguet; Thomas Similowski
Journal:  Intensive Care Med       Date:  2011-10-18       Impact factor: 17.440

Review 2.  Respiratory aspects of neurological disease.

Authors:  M I Polkey; R A Lyall; J Moxham; P N Leigh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.